Covis Pharma delays syndication effort on $350 million equivalent bonds amid weak demand

By Paul A. Harris

Portland, Ore., Feb. 4 – Covis Pharma delayed the pricing of a downsized $350 million equivalent euro-denominated offering of Covis Finco Sarl five-year first-lien senior secured notes (B2/B), market sources say.

The deal, which is facing weak demand, was downsized to $350 million equivalent from $850 million equivalent with the elimination of a proposed $475 million dollar-denominated tranche, according to market sources.

The remaining downsized $350 million equivalent euro-denominated tranche (from $375 million equivalent) came into the market in late January with initial guidance in the 7% area.

The deal is possible business for the Feb. 7 week, a trader said.

Barclays is the left bookrunner. HSBC, Mizuho, MUFG, BNP Paribas and RBC are the joint bookrunners.

The Rule 144A and Regulation S for life notes come with two years of call protection.

Proceeds from the downsized bond offering were shifted to concurrent term loans, which grew to $850 million from $350 million.

The Zug, Switzerland-based specialty pharmaceutical company plans to use the proceeds plus proceeds from the upsized $850 million term loans to refinance debt, including debt incurred to finance products acquired from AstraZeneca.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.